RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Emergent BioSolutions Stock

Emergent BioSolutions Equity 2025

Emergent BioSolutions Equity

649.3 M USD

Ticker

EBS

ISIN

US29089Q1058

WKN

A0LC2W

In 2025, Emergent BioSolutions's equity was 649.3 M USD, a -53.21% increase from the 1.39 B USD equity in the previous year.

Emergent BioSolutions Aktienanalyse

What does Emergent BioSolutions do?

Emergent BioSolutions Inc is a biotechnology company specializing in the development of products for protection against biological threats, infectious diseases, and cancer. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland, USA. Emergent BioSolutions' business model is based on developing and marketing innovative products for the protection of public health and national security. The company aims to respond to known and unknown threats and focus on the changing healthcare needs of society. Emergent BioSolutions operates in four business segments: Biosavérica, Vaccines, Therapeutics, and Contract Manufacturing. Biosavérica is a Latin American subsidiary specializing in the distribution of biological products in Central and South America. Vaccines develops and produces vaccines for infectious diseases such as anthrax, cholera, and typhoid. Therapeutics focuses on the development of anti-infectives and cancer therapeutics. Contract Manufacturing offers services to the biopharmaceutical industry, including the manufacturing, development, and analysis of biopharmaceutical products. Emergent BioSolutions' products include vaccines, antitoxins, antibodies, and therapeutics. One of their most well-known products is BioThrax, an anthrax vaccine used by the US government for defense against biological threats since 2002. Other products include the cholera vaccine Vaxchora, the flu medication FluBlok, and the antibody Anthim used for anthrax. Emergent BioSolutions has partnerships with various governments and organizations worldwide, including the US government, the European Commission, and the World Health Organization. This collaboration aims to ensure that Emergent BioSolutions provides products and services in the areas of national security and public health and enables a rapid response in the event of epidemics and pandemics. In recent years, Emergent BioSolutions has also made several acquisitions to strengthen its business. In 2017, they acquired Cangene Corporation, a company specialized in the manufacture of anti-infectives and antitoxins. In 2019, Emergent BioSolutions acquired PaxVax, a company developing vaccines for infectious diseases, and Adapt Pharma, a company specializing in antidotes for opioid overdose. Emergent BioSolutions is a company focused on innovative research and development, offering products for the protection of public health and national security. The company has experienced significant growth in recent years and strives to adapt to the changing healthcare needs of society. Emergent BioSolutions ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Emergent BioSolutions's Equity

Emergent BioSolutions's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Emergent BioSolutions's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Emergent BioSolutions's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Emergent BioSolutions's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Emergent BioSolutions’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Emergent BioSolutions stock

What is the equity of Emergent BioSolutions this year?

Emergent BioSolutions has equity of 649.3 M USD this year.

What was the equity of Emergent BioSolutions compared to the previous year?

The equity of Emergent BioSolutions has increased/decreased by -53.21% decreased compared to the previous year.

What impact does a high equity have on investors of Emergent BioSolutions?

A high equity is advantageous for investors of Emergent BioSolutions as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Emergent BioSolutions?

A low equity can be a risk for investors of Emergent BioSolutions, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Emergent BioSolutions affect the company?

An increase in equity of Emergent BioSolutions can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Emergent BioSolutions affect the company?

A reduction in equity of Emergent BioSolutions can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Emergent BioSolutions?

Some factors that can affect the equity of Emergent BioSolutions include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Emergent BioSolutions so important for investors?

The equity of Emergent BioSolutions is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Emergent BioSolutions take to change the equity?

To change equity, Emergent BioSolutions can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Emergent BioSolutions pay?

Over the past 12 months, Emergent BioSolutions paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Emergent BioSolutions is expected to pay a dividend of 0 USD.

What is the dividend yield of Emergent BioSolutions?

The current dividend yield of Emergent BioSolutions is .

When does Emergent BioSolutions pay dividends?

Emergent BioSolutions pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Emergent BioSolutions?

Emergent BioSolutions paid dividends every year for the past 0 years.

What is the dividend of Emergent BioSolutions?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Emergent BioSolutions located?

Emergent BioSolutions is assigned to the 'Health' sector.

Wann musste ich die Aktien von Emergent BioSolutions kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Emergent BioSolutions from 1/8/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/8/2025.

When did Emergent BioSolutions pay the last dividend?

The last dividend was paid out on 1/8/2025.

What was the dividend of Emergent BioSolutions in the year 2024?

In the year 2024, Emergent BioSolutions distributed 0 USD as dividends.

In which currency does Emergent BioSolutions pay out the dividend?

The dividends of Emergent BioSolutions are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Emergent BioSolutions stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Emergent BioSolutions

Our stock analysis for Emergent BioSolutions Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Emergent BioSolutions Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.